| pubmed-article:12729659 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12729659 | lifeskim:mentions | umls-concept:C0034255 | lld:lifeskim |
| pubmed-article:12729659 | lifeskim:mentions | umls-concept:C0034424 | lld:lifeskim |
| pubmed-article:12729659 | lifeskim:mentions | umls-concept:C1538051 | lld:lifeskim |
| pubmed-article:12729659 | lifeskim:mentions | umls-concept:C2916808 | lld:lifeskim |
| pubmed-article:12729659 | lifeskim:mentions | umls-concept:C0449560 | lld:lifeskim |
| pubmed-article:12729659 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:12729659 | pubmed:dateCreated | 2003-5-5 | lld:pubmed |
| pubmed-article:12729659 | pubmed:abstractText | A series of 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and analogous quinolines was prepared and evaluated as NR1/2B subtype selective NMDA receptor antagonists. 2-Hydroxyalkylamino substitution combines high affinity with selectivity (vs alpha1 and M1 receptors) and activity in vivo. | lld:pubmed |
| pubmed-article:12729659 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12729659 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12729659 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12729659 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12729659 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12729659 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12729659 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12729659 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12729659 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12729659 | pubmed:month | May | lld:pubmed |
| pubmed-article:12729659 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:12729659 | pubmed:author | pubmed-author:AlanineAlexan... | lld:pubmed |
| pubmed-article:12729659 | pubmed:author | pubmed-author:GillRamanjitR | lld:pubmed |
| pubmed-article:12729659 | pubmed:author | pubmed-author:TrubeGerhardG | lld:pubmed |
| pubmed-article:12729659 | pubmed:author | pubmed-author:MutelVincentV | lld:pubmed |
| pubmed-article:12729659 | pubmed:author | pubmed-author:PinardEmmanue... | lld:pubmed |
| pubmed-article:12729659 | pubmed:author | pubmed-author:BoursonAnneA | lld:pubmed |
| pubmed-article:12729659 | pubmed:author | pubmed-author:BüttelmannBer... | lld:pubmed |
| pubmed-article:12729659 | pubmed:author | pubmed-author:WylerRenéR | lld:pubmed |
| pubmed-article:12729659 | pubmed:author | pubmed-author:HeitzMarie-Pa... | lld:pubmed |
| pubmed-article:12729659 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12729659 | pubmed:day | 19 | lld:pubmed |
| pubmed-article:12729659 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:12729659 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12729659 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12729659 | pubmed:pagination | 1759-62 | lld:pubmed |
| pubmed-article:12729659 | pubmed:meshHeading | pubmed-meshheading:12729659... | lld:pubmed |
| pubmed-article:12729659 | pubmed:meshHeading | pubmed-meshheading:12729659... | lld:pubmed |
| pubmed-article:12729659 | pubmed:meshHeading | pubmed-meshheading:12729659... | lld:pubmed |
| pubmed-article:12729659 | pubmed:meshHeading | pubmed-meshheading:12729659... | lld:pubmed |
| pubmed-article:12729659 | pubmed:meshHeading | pubmed-meshheading:12729659... | lld:pubmed |
| pubmed-article:12729659 | pubmed:meshHeading | pubmed-meshheading:12729659... | lld:pubmed |
| pubmed-article:12729659 | pubmed:meshHeading | pubmed-meshheading:12729659... | lld:pubmed |
| pubmed-article:12729659 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12729659 | pubmed:articleTitle | 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists. | lld:pubmed |
| pubmed-article:12729659 | pubmed:affiliation | Pharma Division, Discovery Chemistry, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland. bernd.buttelmann@roche.com | lld:pubmed |
| pubmed-article:12729659 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:12729659 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12729659 | lld:pubmed |
